Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis.

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, Howlett C, Skarbnik A, Cheson BD, Zent C, Pu J, Kiselev P, Goy A, Claxton D, Isaac K, Kennard KH, Timlin C, Landsburg D, Winter A, Nasta SD, Bachow SH, Schuster SJ, Dorsey C, Svoboda J, Barr P, Ujjani CS.

Haematologica. 2018 May;103(5):874-879. doi: 10.3324/haematol.2017.182907. Epub 2018 Feb 1.

2.

Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience.

Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu JJ, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM.

Blood. 2016 Nov 3;128(18):2199-2205. Epub 2016 Sep 6.

PMID:
27601462
3.

What appears safe is sometimes not: a reason for caution.

Bachow SH, Lamanna N.

Blood. 2016 May 19;127(20):2367-8. doi: 10.1182/blood-2016-03-706259. No abstract available.

PMID:
27207319
4.

Emerging therapies in relapsed and refractory peripheral T-cell lymphoma.

Bachow SH, O'Connor OA.

Clin Adv Hematol Oncol. 2015 Dec;13(12):837-46. Review.

PMID:
27058850
5.

Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.

Bachow SH, Lamanna N.

Curr Hematol Malig Rep. 2016 Feb;11(1):61-70. doi: 10.1007/s11899-016-0298-1. Review.

PMID:
26951237

Supplemental Content

Loading ...
Support Center